Free Trial
NASDAQ:TTNP

Titan Pharmaceuticals 5/14/2025 Earnings Report

Titan Pharmaceuticals logo
$3.95 -0.04 (-1.10%)
Closing price 08/29/2025 03:56 PM Eastern
Extended Trading
$3.98 +0.03 (+0.73%)
As of 08/29/2025 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Titan Pharmaceuticals EPS Results

Actual EPS
-$0.62
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Titan Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Titan Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Titan Pharmaceuticals Earnings Headlines

Small Washington, DC Group Could Crash US Stocks
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."tc pixel
Titan Pharmaceuticals Inc (TTNP) - Investing.com
See More Titan Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Titan Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Titan Pharmaceuticals and other key companies, straight to your email.

About Titan Pharmaceuticals

Titan Pharmaceuticals (NASDAQ:TTNP), a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

View Titan Pharmaceuticals Profile

More Earnings Resources from MarketBeat